BMS-955176
- Generic Name
- BMS-955176
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H62N2O4S
- CAS Number
- 1392312-45-6
- Unique Ingredient Identifier
- 4CA9IAU7RJ
- Background
BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).
- Associated Conditions
- -
- Associated Therapies
- -
Taste Properties of HIV Inhibitor
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 8
- Registration Number
- NCT02608918
- Locations
- πΊπΈ
GSK Investigational Site, Woburn, Massachusetts, United States
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT02578277
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 210
- Registration Number
- NCT02415595
- Locations
- π¬π§
GSK Investigational Site, Tooting, London, United Kingdom
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 86
- Registration Number
- NCT02386098
- Locations
- πΉπ
GSK Investigational Site, Bangkok, Thailand
Food Effect Study With BMS-955176
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT02273947
- Locations
- π¬π§
GSK Investigational Site, Ruddington Fields, Nottinghamshire, United Kingdom
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 21
- Registration Number
- NCT02206711
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
Study of Combined Oral Contraceptive Effects in Female Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 46
- Registration Number
- NCT02157467
Relative Bioavailability Study With BMS-955176
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 47
- Registration Number
- NCT02095886
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 107
- Registration Number
- NCT01803074
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath